Resultados de Pesquisa

INGLÊS

Drugs For Her-2-Positive Breast Cancer

171,59€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 Growth factor receptors have long been known to drive malignant transformation and cancer progression. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2 positive advanced metastatic breast cancer, a new era has started for therapy of this malignant disease.
INGLÊS

Gene Therapy For Autoimmune And Inflammatory Diseases

237,84€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 In this monograph about gene therapy of autoimmune and inflammatory d- orders we have gathered international experts and leaders from different fields to review the state of the art advances on topics ranging from disease entities to vectors and engineered cells.
INGLÊS

Glutamate-Based Therapies For Psychiatric Disorders

171,59€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 This volume offers a unique, contemporary overview of preclinical and clinical evidence that modulating glutamatergic tone is an effective means of treating psychiatric disorders ranging from depression and anxiety to schizophrenia and drug abuse.
INGLÊS

Treatment And Prevention Of Malaria - Antimalarial Drug Chemistry, Action And Use

171,59€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 Starting with an overview of the disease and its current political, financial and technical context, this Milestones in Drug Therapy volume describes the history, chemistry, mechanisms of action and resistance, preclinical and clinical use, pharmacokinetics and safety and tolerability of the current range of antimalarial drugs.
INGLÊS

Twenty Years Of G-Csf - Clinical And Nonclinical Discoveries

237,84€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 This volume in the Milestones in Drug Therapy series describes the past 20 years of treatment with recombinant human G-CSF, including basic science, the use of G-CSF in both the oncology and non-oncology settings, and the safety and economics of its use.
INGLÊS

Tamoxifen - Pioneering Medicine In Breast Cancer

de Philipp Y. Maximov, Russell E. Mcdaniel e V. Craig Jordan

211,34€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 Tamoxifen
INGLÊS

Indacaterol - The First Once-Daily Long-Acting Beta2 Agonist For Copd

118,59€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 Here is a comprehensive overview of the development of Onbrez Breezhaler, a newly approved once-daily inhaled beta2 agonist for treating COPD. Covers design and pre-clinical pharmacology of the molecule, early clinical development, efficacy studies and more.
INGLÊS

Treatment Of Cystic Fibrosis And Other Rare Lung Diseases

158,34€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 This volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions.It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.
INGLÊS

Ace Inhibitors

59,61€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 Angiotensin converting enzyme inhibitors (ACEI) represent the first class of antihypertensive agents that was designed and developed on the basis of a well-defined physiopathological axis of arterial hypertension, a vascular dis order that is now becoming one of the major causes of morbidity/mortality, not only in developed societies but also in the highly populated developing coun tries [1]. CAPTOPRIL, the prototype of the "PRIL" family, which now comprises more than 40 molecule-species, was quite hazardous and the clinical develop ment almost failed when serious side-effects were reported in an alarmist fash ion in reputable scientific journals, such as the New England Journal of Medicine and Lancet. Squibb & Sons came very close to withdrawing CAPTOPRIL from clinical investigation [2]. However, after re-examination of the data obtained from different categories of patients and appropriate dose-adjustments, the clinical use of CAPTOPRIL turned out to be revolutionary. The prototype, as well as other members of the "PRIL" family became the starting point for numerous basic and clinical research programs, focusing on the interactions of ACEI with the kinin, endothelin, and nitric oxide systems, and the contribution of the receptors for AT I, AT 2, bradykinin Bland B , ETA and ET B to the pharmacological actions 2 of the respective peptides. This research activity led to the development of new pharmacological agents, such as the angiotensin receptor antagonists and, more recently, the neutral endopeptidase inhibitors. In the near future, bradykinin receptor antagonists also will be available to modulate ACEI phar macological actions.
INGLÊS

Calcium Channel Blockers

de Theophile Godfraind

171,59€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 The main effect of calcium channel blockers is the blockade of calcium entry into cells through voltage operated calcium channels. This volume gives a comprehensive overview of the different classes of CCBs and their various effects. It covers historical development, pharmacology, clinical aspects, and perspectives.
INGLÊS

Cognitive Enhancing Drugs

118,59€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 During the past decade research into the pharmacology of cognition, particularly regarding learning and memory, has supported the concept that many potential neural targets exist for the development of cognitive-enhancing drugs.
INGLÊS

Combination Therapy Of Aids

171,59€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 An extensive assessment of combination therapy of AIDS. Main focus is put on the Highly Active Antiretroviral Therapy (HAART) but other therapies like salvage therapy are also discussed. The chapters cover efficacy, treatment, causes of treatment failure, clinical care, guidelines, pharmacology.
INGLÊS

Cox-2 Inhibitors

171,59€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 COX-2 inhibitors are important drugs with analgesic and anti-inflammatory effects. This book presents both pre-clinical and clinical information and is important for clinicians interested in the latest information about this class of drugs, for researchers and for students in the field.
INGLÊS

Hepatitis Prevention And Treatment

171,59€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 Chronic viral hepatitis has emerged as one of the most common causes of disease and death worldwide. Because of their unique modes of replication and intimate association with the host immune system, hepatitis B virus (HBV) and hepatitis C virus (HCV) pose challenging problems to scientists in basic and applied research as well as to clinicians engaged in disease management. Although approved antiviral therapy is available for chronic HBV, the emergence of viral resistance provides a rationale for the development of novel chemotherapeutic agents. The lack of a robust cell culture system for HCV replication and a readily accessible small-animal model of HCV infection have hampered the development of antiviral agents for HCV. Neverthe-less, new antiviral agents targeting HCV are now in preclinical and clinical development.This monograph, providing an up-to-date overview of the field of Hepatitis Prevention and Treatment, includes contributions from internationally recognized experts in the field of viral hepatitis, and covers the current state of knowledge and practice regarding the molecular biology, immunology, biochemistry, pharmacology and clinical aspects of chronic HBV and HCV infection. The volume includes salient topics such as: the history and epidemiology of HBV and HCV; recent insights into the molecular mechanisms of viral replication; the host immune response to infection and a discussion of the use (HBV) or potential development (HCV) of vaccines; the current standard of care for chronically-infected patients; and emerging therapies and issues associated with current antiviral treatments. The latest information to researchers and clinicians actively engaged in viral hepatitis research is provided, but also sufficient background and discussion of the literature to benefit the newcomer to the field.
INGLÊS

Sildenafil

264,34€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 This drug is a landmark discovery, which consequently has become the definitive therapy for the treatment of erectile dysfunction (ED). Following the major breakthrough in the field of nitric oxide (NO)-physiology and pharmacology leading to sildenafil being marketed, the most current information is presented in this reference book, including ongoing research from several disparate groups about NO as endothelium-derived relaxing factor (EDRF) and also as a neurotransmitter for nerves innervating erectile tissue in mammals.The development of sildenafil as an oral phosphodiesterase-5 (PDE5) inhibitor drug for the treatment of ED resulted in one of the first products, which made its way successfully from basic NO research to routine clinical therapy.This volume addresses all fields of sildenafil application in both men and women. In a highly competitive research environment with a critical medical need for drug improvements the reader will learn more about clinical resistance to sildenafil treatment and the modalities to overcome the failure rates. The individual chapters cover clinical use, pharmacokinetics, pharmacodynamics, biochemistry, and cultural aspects. They are written by leading experts in their respective fields. Therefore, readers - whether professionals in the pharmaceutical industry, physicians treating ED, biochemists, chemists or pharmacologists - will find a detailed and up-to-date knowledge base about current research activities and an excellent overview for further research on this compound class and its cultural impact.
INGLÊS

Macrolide Antibiotics

171,59€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 There are only very few chemical classes of antibiotics in medical use, and these have originated over a span of more than 60 years of research. Almost half a century ago, the first member of the macrolides, erythromycin, was introduced as a treatment option for bacterial infections. Erythromycin is a very complex fermentation product obtained from the soil bacterium Saccharopolyspora ery thraea (originally named Streptomyces erythreus). The success of erythromycin, based on its efficacy and tolerability, stimulated researchers throughout the world to undertake intense efforts to understand the biology and chemistry of macrolides and to use this experience to improve the properties of this compound class. The second generation of macrolides, based on chemical modifications of erythromy cin, is currently being in broad use, especially for treatment of respiratory tract infections. We presently foresee the introduction of a new generation of macro lides, i. e. the ketolides, which have the potential to overcome rising resistance problems. This monograph is intended to give the interested reader an overview on "macrolide experience", covering important areas from basic research to clinical use. Starting from a historic overview, the essential basic parameters - efficacy, pharmacokinetics, pharmacodynamics, and pharmacology - are highlighted in order to introduce the reader to the rationale for clinical use of macrolides. The following group of chapters cover the complex chemistry of the macro lactone structures, giving historic background, basic structure-activity relation ships of various derivatization strategies, and perspectives for future discovery of new semisynthetic macrolide antibiotics.
INGLÊS

Hmg-Coa Reductase Inhibitors

118,59€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 This book deals with statins which have substantially altered the approach to therapy of atherosclerosis and its sequelae. This book not only provides the reader with valuable information but also stimulates further research into the pathogenesis of atherosclerosis and the mechanisms behind the action of effective statins.
INGLÊS

Antidepressants

95,40€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 Important clinical issues as the outcome of long term treatment with antidepressants, the time of onset of the antidepressant response and the limitations of the antidepressants currently available are covered in this monograph. Leading researchers in the area of clinical and experimental psychopharmacology critically assess the progress in their specialist fields. The mechanisms of action of antidepressants are considered, followed by clinical research into the role of the hypothalamic-pituitary-adrenal axis and the immune system in the biology of depression and in response to treatment. The final chapter deals with the important chemical entities now undergoing development as antidepressants. The purpose of this monograph is not only to inform but also to stimulate research into the biology of depression and the mechanisms behind the action of effective antidepressants. This monograph is of interest to psychiatrists, psychologists, pharmacologists, neuroscientists and endocrinologists.
INGLÊS

Recombinant Protein Drugs

171,59€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 Recombinant protein drugs are intimately associated with the impressive success story of the Biotech Industry during the past thirty years, some of them belonging to the most successful pharmaceutical products. More than thirty different proteins are available for a variety of clinical applications, over 300 proteins are presently being evaluated in clinical trials. In this new volume of the MDT series, historical, technical and clinical aspects of recombinant protein drug discovery and development are presented, covering past, present and future highlights. Leading scientists and co-founders of early Biotech companies describe technical breakthroughs and the fascinating story of pioneering discoveries, as well as the long way of translating them into products and business. Therefore, this book represents an exciting documentation of the beginning of a new era in the pharmaceutical industry. In addition, scientists from basic research, clinic and industry actively involved in new developments discuss...
INGLÊS

Glucocorticoids

59,61€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 Following 50 years of glucocorticoid use in a clinical setting, an international body of expert scientists and physicians presents the most expansive survey of glucocorticoid pharmacology to date.
INGLÊS

Modern Immunosuppressives

59,61€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 Expanding from the classic use of immunosuppressants in transplantation and rejection, this current overview highlights their new roles in clinical medicine. Immunosuppressants are at the forefront of new treatment modalities. Individual chapters focus on their use not only in prevention or treatment of transplant rejection, but also on their use in immune-complex and autoimmune diseases, including rheumatoid arthritis; on combination therapies to achieve synergy in immunosuppression; on new drugs, low molecular weight chemicals, the use of antibodies and gene therapy; on immunological tolerance to prevent or inhibit transplant rejection; and how data derived from transplant studies can be applied to other avenues of immunosuppression. Clinicians and researchers will appreciate the scope of the work and the presentation of new approaches in the rapidly developing field of immunosuppression.
INGLÊS

Atypical Antipsychotics

237,84€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill ness, it allowed, for the first time, to adequately control the severe hallu cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro longed treatment, represented a major problem in the treatment of schizo phrenic patients.
INGLÊS

Methotrexate

59,61€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 Although surprising, it seems fitting that a drug developed at the dawn of the era of rational drug design and therapeutics, methotrexate, should remain in common use for the therapy of so many different kinds of illnesses.
INGLÊS

Anxiolytics

118,59€ + 10% EM CARTÃO

DISPONIBILIDADE IMEDIATA

 In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD).
A carregar resultados...

Ver mais resultados